MYELODYSPLASTIC SYNDROME

This early-phase trial tests whether combining tagraxofusp (a targeted therapy) with azacitidine (a chemotherapy-like drug) can safely prevent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) from coming back after a donor stem cell transplant. About 43 adults aged …

This early-stage trial tests a pill called olutasidenib in people with certain blood cancers (AML, MDS, or CMML) who have an IDH1 gene change. The goal is to see if taking this drug after a donor stem cell transplant is safe and can help prevent the cancer from coming back. About…

This early-phase trial tests a combination of three drugs—pembrolizumab, decitabine, and venetoclax—in adults with acute myeloid leukemia or myelodysplastic syndrome that has returned or not responded to prior treatment. The goal is to find the safest dose and see how well the dr…

This study tests a combination of two or three drugs (ivosidenib, venetoclax, with or without azacitidine) in people with certain blood cancers that have an IDH1 mutation. The goal is to find the best dose and see how well the drugs control the cancer. About 96 adults with acute …

This study tests a new medication called SP-420 in about 90 adults with transfusion-dependent β-thalassemia or low-risk myelodysplastic syndromes. The goal is to see how well it removes extra iron from the liver and whether it is safe. Participants take the drug three times a wee…

This study tests a combination of three drugs (ASTX727, venetoclax, and gilteritinib) for people with acute myeloid leukemia or high-risk myelodysplastic syndrome that has a specific gene change called FLT3. The goal is to find the best dose and see how well the drugs work togeth…

This study tests two different methods to lower the risk of graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body, after a stem cell transplant. The trial includes 120 adults with acute leukemia or myelodysplastic syndrome (MDS) whos…

This early-phase trial tests whether adding emapalumab to standard medications can safely prevent graft-versus-host disease (GVHD) in 15 adults with acute myeloid leukemia or myelodysplastic syndrome receiving a reduced-intensity donor stem cell transplant. Emapalumab blocks an i…

This study tests a new device that filters excess iron from the blood in people with myelodysplastic syndrome (MDS) or myelofibrosis who cannot take standard iron-removing medications. Participants will undergo three short dialysis-like sessions over one week. The goal is to see …

This early-phase study tests a new drug called SL-401 combined with standard treatments (azacitidine and venetoclax) in people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN). T…

This early-stage trial tests a drug called SEA-CD70, alone or with standard chemotherapy, in about 178 people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The main goals are to find safe doses and check for side effects. Researchers will also look for sign…

This study tests a new drug called elritercept against a standard treatment (epoetin alfa) for anemia caused by a bone marrow disorder called myelodysplastic syndromes (MDS). About 300 adults who need regular red blood cell transfusions will take part. The goal is to see if elrit…

This study tests a two-step approach for people with advanced myeloproliferative neoplasms (blood cancers). First, patients receive a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) to reduce cancer cells. Then, they undergo a donor…

This early-phase study tests a new drug called FHD-286 combined with two standard chemotherapy drugs (decitabine and venetoclax) in adults with acute myeloid leukemia (AML) that is hard to treat. The main goal is to find the safest dose and watch for side effects. About 33 people…

This early-phase study tests a new drug called rezatapopt combined with azacitidine in 24 adults whose acute myeloid leukemia or myelodysplastic syndrome has a specific TP53 gene mutation (Y220C). The main goal is to check safety and side effects. Participants must have cancer th…

This early-stage study tests a new drug called RPT1G in 24 people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have not responded to standard treatments. The main goals are to check if the drug is safe and to find the best dose. This is not …

This early-stage study is testing a new drug called cirtuvivint, alone or with another drug (ASTX727), in people with blood cancers MDS and AML. The goal is to find the safest dose and see how well it works. About 54 adults whose cancer has returned or not responded to treatment …

This study tests a mix of drugs that calm the immune system and boost white blood cells in people with aplastic anemia or certain types of MDS. The goal is to improve low blood counts by targeting immune cells that may be attacking the bone marrow. About 140 adults will take part…

This study tests a two-step, lower-intensity approach using radiation and chemotherapy before a stem cell transplant for people with various blood cancers or disorders. The goal is to see if this gentler preparation reduces the risk of death from the transplant itself. About 63 p…

This study tests whether adding the drug ruxolitinib to the standard anti-rejection drugs tacrolimus and methotrexate can better prevent graft-versus-host disease (GVHD) in children and young adults (ages 2-22) receiving a bone marrow transplant for blood cancers like leukemia. G…

This early-phase trial tests a genetically modified virus (VSV-IFNβ-NIS) alone or with chemotherapy and immunotherapy drugs in people with blood cancers like multiple myeloma, acute myeloid leukemia, and lymphomas that have returned or not responded to treatment. The virus is des…

This study is for people with certain blood cancers, like leukemia or lymphoma. It tests a stem cell transplant from a half-matched donor, using a special drug combo (treosulfan and fludarabine) plus low-dose radiation to prepare the body. The goal is to see if this approach help…

This study tests whether adding venetoclax to standard chemotherapy before a stem cell transplant can help people with high-risk acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) live longer without their cancer coming back. About 324 adults aged 18 to 70 will receiv…

This study tests a combination of two drugs (enasidenib and azacitidine) in about 50 people with a specific genetic mutation (IDH2) and acute myeloid leukemia that has returned or not responded to prior therapy. The goal is to see if the combination can stop cancer cell growth an…

This study tests a treatment plan for adults aged 60 and older with newly diagnosed, high-risk acute myeloid leukemia (AML) or similar blood cancers. The approach combines strong chemotherapy (FLAG-Ida) with a donor stem cell transplant given just days later, using lower-intensit…

This study tests whether adding venetoclax to a standard chemotherapy regimen (FLAG IDA) can better eliminate leukemia cells in people newly diagnosed with acute myeloid leukemia (AML). About 102 adults aged 18 to 65 will be randomly assigned to receive either the new combination…

This early-stage study tests a new drug, BMS-986497, for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or not responded to treatment. The drug is given alone or with standard medicines (azacitidine and venetoclax) to find the safest…

This study tests whether combining three drugs—quizartinib, decitabine, and venetoclax—can better control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. The trial includes 73 adults aged 60 or older who cannot have standard intensive chemotherapy, or whose ca…

This early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…

This study tests a drug called canakinumab in people with low- or intermediate-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The drug blocks a protein involved in inflammation that may help cancer grow. The goal is to see if it improves blood cou…

This study tests whether combining two drugs—CPX-351 (a chemotherapy) and ivosidenib (a targeted therapy)—can better control acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that have an IDH1 gene mutation. About 30 adults who are either newly diagnosed or…

This early-phase study tests a new stem cell treatment called Orca-T, combined with targeted radiation and chemotherapy, for people aged 60-75 with acute leukemias or myelodysplastic syndrome (MDS). The goal is to find the safest dose and see how well the body tolerates the treat…

This study tests a two-step method of giving an anti-rejection drug (ATG) along with standard medications to prevent severe graft-versus-host disease (GVHD) in people with blood cancers receiving a stem cell transplant. About 56 adults aged 18-75 will participate. The goal is to …

This study tests a refined cord blood transplant method for people with high-risk blood cancers like leukemia and lymphoma. Participants receive chemotherapy and radiation before the transplant to prepare the body, then drugs after to prevent rejection. The goal is to improve sur…

This study tests whether adding enasidenib to standard treatment (ASTX727) improves outcomes for people with a high-risk form of myelodysplastic syndrome (MDS) that has a specific IDH2 gene change. About 54 adults who have not had prior cancer therapy for MDS will be randomly ass…

This early-stage study tests a new type of stem cell transplant for children whose blood cancers or solid tumors have come back or are hard to treat. Doctors use a special method to remove certain immune cells from the donor's stem cells and give a drug called zoledronate after t…

This study tests whether giving patients personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill remaining cancer cells and reduce complications. It includes 100 adults with various blood cancers like leukemia, lymphoma, or multiple mye…

This study tests a combination of four chemotherapy drugs (cladribine, idarubicin, cytarabine, and venetoclax) in people with acute myeloid leukemia, high-risk myelodysplastic syndrome, or a fast-growing form of chronic myeloid leukemia. The goal is to see how well these drugs ki…

This early-stage trial tests a vaccine (CMV-MVA Triplex) given to both stem cell donors and recipients to boost immunity against cytomegalovirus (CMV), a common and dangerous infection after transplant. About 46 people with various blood cancers or disorders will take part. The g…

This study tests a vaccine (CMV-MVA Triplex) given to stem cell donors to help prevent CMV infection in patients receiving a stem cell transplant. The vaccine boosts the donor's immunity against CMV, which is then passed to the patient through the transplant. About 216 donor-reci…

This early-phase study tests whether two metal-removing drugs (edetate calcium disodium and succimer) are safe and can help control acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) when given alongside chemotherapy. About 58 adults with these blood cancers will rece…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home care and if it is safe. Participants will receive their usual cancer drugs either at home or in the clini…

This study tests whether a curcumin supplement can reduce inflammation and improve symptoms in people with certain blood disorders, including CCUS, low-risk MDS, and MPNs. The trial will enroll 30 participants who will receive either curcumin or a placebo for 12 months. Researche…

This study compares giving cancer treatment at home versus in a clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves the overall experience. About 220 participants will be randomly assigned to receive their t…

This study is for people with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS). It aims to develop special lab tests that can find tiny amounts of cancer cells left after treatment, called minimal residual disease. By detecting these cells early, doctors …

This study is a registry that collects information from 1,000 patients with blood diseases who receive stem cell transplants at a hospital on the Qinghai-Tibet Plateau. Researchers will track their health, treatments, and costs over time to learn how high altitude affects recover…

This study collects tissue and fluid samples (like blood, urine, and tumor biopsies) from up to 5,000 children and adults with cancer. The samples are used for research to better understand cancer and develop new tests or treatments. Participants do not receive any experimental t…

This study is creating a large database of people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records and follow participants over time to learn about disease patterns, treatments, and…

This study watches 45 people with neuroendocrine tumors who are getting or have gotten peptide radionuclide therapy (PRRT). Researchers will test blood samples over up to 5 years to find genetic changes that might lead to myelodysplastic syndrome or acute myeloid leukemia. The go…

This study screens 2,000 adults with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome. Researchers test blood and bone marrow for specific markers to see if participants can join a treatment trial that targets their cancer type. The goal is to make the matching …

This study screens children and young adults (up to age 22) whose leukemia has returned or is difficult to treat. By testing their blood and bone marrow, doctors look for specific genetic markers to match them with the most promising experimental treatments. The goal is to improv…